Furthr is the benefit of climate feel-good!Each month, our subscribers plant protected trees and reduce carbon emissions on world-leading climate projects. As a reward, each of our subscribers has the chance of winning prizes in our exciting monthly prize draws, with experiences, cash & eco goodies up for grabs!Our trees restore wildlife habitats and create employment for local poverty-stricken communities, whilst our renewable energy solutions prevent carbon emissions entering our atmosphere and fast-track the shift to green energy where these solutions could not exist without funding from initiatives like ours.This support enables each subscriber to become personally climate-positive in their life, and they're kept up-to-date with their progress and personal impact on our projects through their online profile and monthly email.

Having invested in and successfully exited Logos Technologies at the end of their earn out, as a result of delivering rapid profitable growth, I am now using that experience to consult and work with start up and scale up disruptive digital and eclinical businesses to bring them to market. Using my strong pedigree in Business Development and General Management, coupled with diverse B2B & B2C experience, I have worked in a range of sectors including med tech, clean tech, air purification & pollution control, medical devices and analytics. I am open to other adjacent sectors where innovation and being a force for good is at the heart of the business strategy.Various achievements for clients · Interim VP Business Development at eclinical start up - Successfully introduced into the clinical trial space, signing £750k of contracts from scratch. Designed and implemented pricing and value strategy, returned post Series A for further period· Interim Commercial Director at Med Tech scale up - Redeveloped commercial strategy cutting costs and opening new pipeline >£2m· Interim CEO for University spin out of analytical device - Successfully led InnovateUK grant application· Commercial Advisor for medical device scale up prior to Series A. Managed & refined pipeline, sales channels and developed sales opportunities and network into the NHS & beyond

ECC/Yellow Collective was built on my initial vision to transform the built environment into ‘trees’ by a daylight activated coating that was CO2 reducing, pollution busting and pathogen killing. I founded the company, built the team, raised investment and won the first deal with a global engineering firm, influencing heavily at C-suite and project managed delivery of the project on time, in full. Responsible for defining and articulating the vision, sales and marketing, fundraising, project delivery, product development, investor relations and leadership. Key achievements;· Successfully raised initial SEIS/EIS round· Established laboratory and testing regimes for efficacy proof, leading product development · Built qualified pipeline for >£15m across a number of verticals· Closed 3 x deals with global engineering firm and then project managed to deliver on time in full· Successful trial in global hotel chain, plus numerous others agreed including with global outdoor advertising company· Developed B2B, B2G & B2C marketing development and campaign plans

I founded Environmental Control Coatings to research and develop a range of proprietary technologies to combat both internal and external air pollution. This is done by accelerating natural processes and destroying the pollution for the benefit of both the environment & human health. Initial focus has been on protective photocatalytic coatings, with our first patent pending.

Reporting directly to CEO, responsible for P&L of the Clinical Business Unit of Instem PLC. Responsible for the strategic & commercial development of the ALPHADAS proposition. Leading the re-generation of the software development process & code update as well as the integration of the former Logos Technologies Business Unit into the parent PLC.· Led re-design of software development process to Agile using Kanban· Embedded long term plan to re-structure software team from outsource to internal Indian resource· Managed client relationships through problematic software implementations to positive outcomes· Integral in expanding clinical knowledge to wider sales force· Created & hit P&L targets, revenue £3m

Responsible for Global Sales & Commercial Development of ALPHADAS, the worlds leading early phase eSource EDC.Responsible for stabilising & growing Logos Technologies in key markets globally· Worked extensively with CEO to successfully resolve initial corporate challenges regarding ownership· Worked in partnership with CEO to secure sale to Instem PLC· Signed over $4 million in new License fees in turgid market against backdrop of corporate instability · 12 new clients across 4 continents· Grew annually recurring revenue from under $100k to over $1m· Grew pipeline to over $7 million· Responsible for Marketing and PR – successfully launched new website and creative execution· Managed team through corporate change and designed new company culture and HR structureI originally joined Logos Technologies in May 2010, and together with the CEO & Founder successfully sold the business to Instem PLC in May 2013. I was then responsible for transitioning all clients to Instem & secure new business to hit ambitious earn out targets · Exceeded all targets – earn out achieved two years ahead of time· Won 3 of the largest deals in Instem’s history – c.$8m revenue over 5 years (Instem Annual EBIT at time was circa $1.8m)· Led new marketing and other integration projects

UBC acquired CDR in August 2009· Only member of global BD team of 9 to remain in post after CDR’s acquisition by UBC· Responsible for managing, developing & leveraging relationships within existing pharma and biotech clients to identify new business opportunities globally· Trained existing salesforce in the CDR product and science behind it (300+ peer review papers)

Business Development and Marketing Strategy for CDR across existing and new accounts - within Europe, India, Japan, South Africa and the US.Responsible for growing CDR into new areas geographically, therapeutically and into later phase trials, whilst developing current client base and expanding traditional areas of strength · Won largest program of studies in CDR’s history - equivalent to the company’s entire 2008 turnover· 2009 - 80% of target hit with 66% of time gone – vs rest of company at 20% of target· Wrote and implemented global large pharma development plan for entire company· Completed four ‘non project’ RFIs, securing preferred provider status with 3 Top 10 pharma companies · Co-developed (with U.S. VP of BD) new proposal document and pricing matrix and new company marketing strategy · Conceived and managed targeted experience matrix to focus new business drive · Conceived CDR experience matrix, by phase of trial, indication and scientific papers published· Podium presentations delivering scientific and commercial messaging. Published 4 times· Responsible for managing, developing and leveraging relationships within existing pharma and biotech clients to identify new business opportunities

Late Phase Clinical Trials Business Development, account base within EuropeResponsible for sourcing, developing and winning Full Service Clinical Trials from client base varying from ‘virtual’ to large Pharma & Biotech · Key achievements:· Won £2 million from 5 clinical trials and various stand alone service contracts· Developed pipeline of over £7 million · Responsible for winning and developing new business from zero client base· Helped conceive and develop therapeutic market mapping of Chiltern’s key strengths and BD drive

Business Development and Marketing Execution

Business Development and Marketing Strategy and execution for a new media company with exclusive online rights of the National Union of Students.

Sold Branded beers to the free on trade in London

Observed and regulated the open outcry pits of the London International Financial Futures Exchange